medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2012, Number 1

<< Back Next >>

Rev Invest Clin 2012; 64 (1)

Evaluation of breast cancer treatment at a tertiary-level institution with Popular Health Insurance in Mexico

Arce-Salinas C, Lara-Medina FU, Alvarado-Miranda A, Castañeda-Soto N, Bargalló-Rocha E, Ramírez-Ugalde MT, Pérez-Sánchez V, Rivera L, Gambo-Vignole C, Santamaría-Galicia J,Nieves-Casas RI, Morán-Muñoz H, Mohar-Betancourt A

Language: Spanish
References: 28
Page: 9-16
PDF size: 243.80 Kb.


ABSTRACT

Background. In our country, breast cancer represents a major health problem. Only 45% of all population has access to health services, the consequence is delay in diagnosis and treatment. In Mexico, 66% of all new cases of breast cancer are diagnosed in locally advanced stages. From May 2007 the Health System Protection Against Catastrophic Expenses, called Seguro Popular (SP), breast cancer was included in covering the treatment of this neoplasm in any patient without access to social security. Objective. To evaluate the results and impact of SP in the adjuvant and neoadjuvant treatment of a group of patients diagnosed with breast cancer at an institution of national reference. Material and methods. We analyzed a group of 259 patients in stages (I-IIIC). The clinical stages I and II (55 patients) were treated with adjuvant chemotherapy FAC -T (fluorouracil 500 mg/m2, adriamycin 50 mg/m2 and cyclophosphamide 500 mg/m2 (FAC) followed by 12 weeks of paclitaxel 80 mg/m2 ± trastuzumab loading dose of 4 mg/kg followed by 2 mg/kg); 204 patients in locally advanced stages (IIB-IIIC) received FAC-T ± trastuzumab followed by surgery. Adjuvant treatment consisted of endocrine therapy for hormone-sensitive patients and radiotherapy 50 cGy according to international standards. Results. The age at diagnosis was 47 years (range 23-68). 80% of them were locally advanced stages (IIB-IIIC) and were treated in a neoadjuvant setting, 20% was in early stages, treated with surgery and adjuvant chemotherapy. The disease-free survival and overall survival at 30 months was 85.7 and 90% respectively. Overall pathologic complete response was obtained in 15% of cases. In the subgroup analysis showed that 41% of patients HER2 (+), 29% of triple-negative patients and 9% of hormo- ne-sensitive tumors achieved complete pathological response (p = 0.0001). Conclusion. This is the first analysis of efficacy of adjuvant and neoadjuvant treatment in breast cancer since the introduction of popular secure non-entitled population. It is clear that treatment efficacy is similar to that reported in the literature, with 15% of pRC and survival to 30 months in 94-80%. The coverage of health expenditures treats a larger number of patients optimally. Along with this, efforts should be made to reduce the high frequency of diagnosis at advanced stage.


REFERENCES

  1. Dirección General de Epidemiología, Secretaría de Salud. RHNM 2002.

  2. Palacio-Mejía LS, Lazcano-Ponce E, Allen-Leigh B, et al. Diferencias regionales en la mortalidad por cáncer de mama y cérvix en México entre 1979 y 2006. Sal Púb Méx 2009; 51(Supl. 2): S208-S219.

  3. Porter PL. Global trends in breast cancer incidence and mortality. Sal Pub Mex 2009; 51(Supl. 2): S141-S146.

  4. Schwartsmann G. Breast cancer in South America: challenges to improve early detection and medical management of a public health problem. J Clin Oncol 2001; (Suppl. 18): 118S- 124S.

  5. Adebamowo CA, Adekunle OO. Case controlled study of the epidemiological risk factor for breast cancer in Nigeria. Br J Surg 1999; 86: 665-8.

  6. Lozano-Ascencio R, Gómez-Dantés H, Lewis S, et al. Tendencias del cáncer de mama en América Latina y El Caribe. Sal Púb Méx 2009; 51(Supl. 2): S147-S156.

  7. Knaul FM, Nigenda G, Lozano R, et al. Cáncer de mama en México: una prioridad apremiante. Sal Púb Méx 2009; 51(Supl. 2): S335-S344.

  8. Educational Book 2004, 40th Annual Meeting ASCO.

  9. El Saghir NS, Eniu A, Carlson RW, et al. Locally advanced breast cancer treatment guideline implementation with particular attention to low-and middle-income countries. Cancer 2008; 103 (Suppl. 8): 2315-24.

  10. Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005; 23: 9304-11.

  11. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B18. J Natl Cancer Inst Monogr 2001; 30: 96-102.

  12. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-44.

  13. Buzdar A, et al. Proc ASCO 2004; 23: 7 (Abstract 520).

  14. Hurley J, Doliny Ph, Reis I, et al. Docetaxel, cisplatin and trastuzumab as a primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006; 24: 1831-8.

  15. Peto R. The worldwide overview: new results for systemic adjuvant therapies. Plenary Lecture. 30th Annual San Antonio Breast Cancer Symposium San Antonio, TX. 2007.

  16. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.

  17. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER- 2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-14.

  18. Kwan ML, Kushi LH, Weltizien E, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Research 2009; 11: R31 [Doi:10.1186/bcr2261].

  19. Dent R, Trudeau M, Pritchard KI, et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34.

  20. Carey L, Perau CM, Livasy CA, et al. Race, breast cancer subtypes and survival in the Carolina breast cancer study. JAMA 2006; 295: 2492-502.

  21. Abdullah N, Hisham, Cheng-Har Y. Overview of breast cancer in Malaysian women: a problem with late diagnosis. Asian J Surg 2004;2 7: 130-3.

  22. Sant M, Allemani C, Berrino F, et al. Breast cancer survival en Europe and the United States. A population based study. Cancer 2004; 100: 715-22.

  23. Mohar A, Bargalló E, Ramírez MT, Lara F, Beltrán-Ortega A. Recursos disponibles para el tratamiento del cáncer de mama en México. Sal Púb Méx 2009; 51 (Supl. 2): S263-S269.

  24. Martínez-Montañez OG, Uribe-Zúñiga P, Hernández-Ávila M. Políticas públicas para la detección del cáncer de mama en México. Sal Púb Méx 2009; 51(Supl. 2): 350-60.

  25. Brandan ME, Villaseñor Y. Detección del cáncer de mama: estado de la mamografía en México. Cancerología 2006; 1: 147-62.

  26. Hortobagyi G, De la Garza Salazar J, Pritchard K, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005; 6: 391-401.

  27. Davidson NE, Morrow M. An assessment of neoadjuvant systemic therapy for breast cancer. J Natl Cancer Inst 2005; 97: 159-61.

  28. Veronesi U, Bonadonna G, Zurrida S, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995; 222: 612-8.




2020     |     www.medigraphic.com